Therapy of bronchial asthma in children: age-related aspects

Cover Page

Cite item


Bronchial asthma (BA) is a disease that is one of the most frequent chronic diseases of childhood. Characteristic clinical symptoms of BA are wheezing, cough, difficulty in breathing, shortness of breath and, of course, recurrent episodes of bronchial obstruction. They require mandatory clarification of family and individual allergoanamnesis, assessment of symptoms, differential diagnosis with other diseases that may occur with BA. The Global Initiative for the Treatment and Prevention of Bronchial Asthma (GINA 2020–2021) preserves and develops the ageappropriate approach to verification of diagnosis and therapy selection, which is supported in the Russian National Program "Bronchial Asthma in Children" and in the Russian clinical guidelines "Bronchial Asthma 2021 When the diagnosis of BA is made, therapy should be started as early as possible. Administration of low-dose inhaled glucocorticosteroids (IGCS) immediately after the diagnosis allows not only to control the inflammatory process, which is the basis of BA, but also to reduce the severity of exacerbations. IGCS are the most effective drugs for children of any age, they ensure control of the disease and reduce the risk of AD exacerbations.

Full Text

Restricted Access

About the authors

Natalia A. Geppe

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
ORCID iD: 0000-0003-0547-3686

D. Sci. (Med.), Prof., Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Elena G. Kondiurina

Novosibirsk State Medical University


D. Sci. (Med.), Prof., Novosibirsk State Medical University

Russian Federation, Novosibirsk

Vera A. Reviakina

Federal Research Centre of Nutrition and Вiotechnology

ORCID iD: 0000-0002-1149-7927

D. Sci. (Med.), Prof., Federal Research Centre of Nutrition and Вiotechnology

Russian Federation, Moscow

Aleksandr B. Malakhov

Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0002-2686-8284

D. Sci. (Med.), Prof., Sechenov First Moscow State Medical University

Russian Federation, Moscow

Natalia G. Kolosova

Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0001-5071-9302

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow


  1. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд., перераб. и доп. М.: Оригинал-макет, 2017 [National program “Bronchial asthma in children. Treatment strategy and prevention”. 5th ed., reprint. and additional. Moscow: Original-maket, 2017 (in Russian)].
  2. Геппе Н.А., Колосова Н.Г., Зайцева О.В., и др. Диагностика и терапия бронхиальной астмы у детей дошкольного возраста. Место небулизированных ингаляционных глюкокортикостероидов в терапии бронхиальной астмы и крупа (Консенсус по результатам совета экспертов Педиатрического респираторного общества). Российский вестник перинатологии и педиатрии. 2018;63(3):124-32 [Geppe NA, Kolosova NG, Zaytseva OV, et al. Diagnostic and treatment of bronchial asthma in children of preschool age. Place of nebulized inhaled glucocorticosteroids in treatment of bronchial asthma and croup (Consensus on the results of the council of experts of the pediatric respiratory society). Rossiyskiy vestnik perinatologii i pediatrii. 2018;63(3):124-32 (in Russian)]. doi: 10.21508/1027-4065-2018-63-3-124-132
  3. Бронхиальная обструкция на фоне острой респираторной инфекции у детей дошкольного возраста: диагностика, дифференциальная диагностика, терапия и профилактика. Согласованные рекомендации экспертов. М.: МедКом-Про, 2019 [Bronchial obstruction against the background of acute respiratory infection in preschool children: diagnosis, differential diagnosis, therapy and prevention. Agreed expert recommendations. Moscow: MedKom-Pro, 2019 (in Russian)].
  4. Carroll WD, Wildhaber J, Brand PLP. Parent misperception of control in childhood/adolescent asthma: the Room to Breathe survey. Eur Respir J. 2012;39:90-6. doi: 10.1183/09031936.00048911
  5. Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroid in asthma. Chest. 1995;108(5):1228-34. doi: 10.1378/chest.108.5.1228
  6. Selroos O. Effect of disease duration on dose-response of inhaled budesonide in asthma. Respir Med. 2008;102(7):1065-72. doi: 10.1016/j.rmed.2007.12.029
  7. Selroos O, Löfroos AB, Pietinalho A, Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study. Respir Med. 2004;98(3):254-62. doi: 10.1016/j.rmed.2003.10.007
  8. Бронхиальная астма. Федеральные клинические рекомендации. Российское респираторное общество (РРО). 2019. Режим доступа: Ссылка активна на 14.09.2020 [Bronkhial'naia astma. Federal'nye klinicheskie rekomendatsii. Rossiiskoe respiratornoe obshchestvo (RRO). 2019. Available at: Accessed 14.09.2020 (in Russian)].
  9. The Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2020. Available at: Accessed: 02.10.2020.
  10. Lavorini F. The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy. 2013;2013:102418. doi: 10.1155/2013/102418
  11. Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308-31. doi: 10.1183/09031936.00166410
  12. Janson C, Lööf T, Telg G, et al. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med. 2016;26:16053. doi: 10.1038/npjpcrm.2016.53
  13. Ramadan WH, Sarkis AT. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: an observational comparative study. Chron Respir Dis. 2017;14(3):309-20. doi: 10.1177/1479972316687209
  14. Williams RO 3rd, Hu C. Moisture uptake and its influence on pressurized metered-dose inhalers. Pharm Dev Technol. 2000;5(2):153-62. doi: 10.1081/pdt-100100530
  15. Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr. 1999;135(1):28-33. doi: 10.1016/s0022-3476(99)70323-9
  16. Pritchard JN, Hatley RH, Denyer J, Hollen DV. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther Deliv. 2018;9(2):121-36. doi: 10.4155/tde-2017-0102
  17. Borghardt GM, Kloft C, Sharma A. Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. Can Respir J. 2018;2018:2732017. doi: 10.1155/2018/2732017
  18. Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol. 2018;53(12):1670-7. doi: 10.1002/ppul.24176
  19. Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120(5):1043-50. doi: 10.1016/j.jaci.2007.08.063
  20. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;2012(5):CD002314. doi: 10.1002/14651858.CD002314.pub3
  21. Camargo CA Jr, Ramachandran S, Ryskina KL, et al. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm. 2007;64(10):1054-61. DOI:0.2146/ajhp060256
  22. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147(2):213-20. doi: 10.1016/j.jpeds.2005.03.052
  23. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-67. doi: 10.1016/s0022-3999(99)00057-4
  24. Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. N Engl J Med. 2019;380(21):2020-30. doi: 10.1056/NEJMoa1901963
  25. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919-28. doi: 10.1016/S0140-6736(19)31948-8
  26. O’Byrne PM, FitzGerald JM, Zhong N, et al. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials. Trials. 2017;18(1):12. doi: 10.1186/s13063-016-1731-4
  27. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40-7. doi: 10.1016/j.jaci.2004.04.042
  28. Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J Asthma. 2005;42(9):715-24. doi: 10.1080/02770900500305748
  29. Государственный реестр лекарственных средств. Режим доступа: Ссылка активна на 22.10.2020 [Gosudarstvennyi reestr lekarstvennykh sredstv. Available at: Accessed 22.10.2020 (in Russian)].
  30. Broeders MEAC, Sanchis J, Levy ML, et al. The ADMIT series – issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009;18(2):76-82. doi: 10.4104/pcrj.2009.00025
  31. Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21(2):208-13. doi: 10.4104/pcrj.2012.00010

Supplementary files

Supplementary Files
1. Fig. 1. Algorithm of bronchial asthma (BA) diagnosis [2, 3].

Download (355KB)
2. Fig. 2. Relationship of delivery conditions and aerosol deposit. Distribution of radiolabeled aerosol in children (3 years) during inhalation: a – through a loose-fitting mask; b – during crying during inhalation; c – during quiet inhalation [15].

Download (71KB)
3. Fig. 3. Nebulas for budesonide suspension.

Download (208KB)
4. Fig. 4. Comparison of the efficacy of montelukast and Pulmicort® suspension: a – proportion of patients who required systemic GCS; b – peak expiratory rate on montelukast therapy and budesonide suspension therapy.

Download (95KB)
5. Fig. 5. Comparison of baseline therapy algorithms for BA according to GINA and the National Program in children aged 0–5 years [1, 9].

Download (413KB)
6. Fig. 6. Therapy algorithm for children aged 6–11 years according to GINA (2020) [9].

Download (268KB)
7. Fig. 7. Therapy for patients 12 years and older [9].

Download (462KB)
8. Fig. 8. Potential outcomes with different BA treatment regimens in response to worsening symptoms [28].

Download (128KB)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies